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Abstract
Purpose: The study aims to assess the feasibility of intensity-modulated and image-guided radiotherapy (IMRT, and IGRT,
respectively) for functional preservation in locally advanced laryngeal cancer. A retrospective review of 27 patients
undergoing concurrent chemoradiation for locally advanced laryngeal cancers (8 IMRT, 19 IGRT) was undertaken. In addition
to regular clinical examinations, all patients had PET imaging at 4 months and 10 months after radiotherapy, then yearly.
Loco-regional control, speech quality and feeding-tube dependency were assessed during follow-up visits.
Results: At a median follow-up of 20 months (range 6–57 months), four out of 27 patients (14.8%) developed local
recurrence and underwent salvage total laryngectomy. One patient developed distant metastases following salvage
surgery. Among the 23 patients who conserved their larynx with no sign of recurrence at last follow-up, 22 (95%) reported
normal or near normal voice quality, allowing them to communicate adequately. Four patients (14.8%) had long-term tube
feeding-dependency because of severe dysphagia (2 patients) and chronic aspiration (2 patients, with ensuing death from
aspiration pneumonia in one patient).
Conclusions and Clinical Relevance: Functional laryngeal preservation is feasible with IMRT and IGRT for locally advanced
laryngeal cancer. However, dysphagia and aspiration remain serious complications, due most likely to high radiation dose
delivery to the pharyngeal musculatures.
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Introduction
Locally advanced laryngeal cancer was traditionally treated with
total laryngectomy followed by postoperative radiotherapy given
the high risk of loco-regional recurrences [1]. However, the
presence of a stoma following total laryngectomy is often
associated with chronic airway irritation and coughing, sleep
difficulties and poor cosmesis [2–4]. Additionally, resection of
large tumors and neck dissection may result in substantial chronic
postoperative pain [5,6]. In an attempt to improve patient quality
of life, the Veterans Administration Laryngeal Study (VALG) first
investigated the feasibility of an organ-preservation approach,
achieving a 64% rate of larynx preservation with induction
chemotherapy followed in responders by definitive radiotherapy,
while maintaining a survival rate comparable to that seen in
laryngectomized patients [7]. The Radiation Therapy Oncology
Group (RTOG) 91–11 Study subsequently demonstrated an even
higher rate of laryngeal preservation with concurrent chemoradia-
tion rather than induction chemotherapy followed by radiotherapy
alone at least for patients with T3 disease [8]. While the exclusion
of patients with T4 lesions from RTOG 91-11 left it unclear
whether laryngeal preservation with concurrent chemoradiation
was feasible for all patients with locally advanced laryngeal cancer
for functional laryngeal preservation, later studies confirmed the
feasibility of such an approach for T4 disease as well [9,10].
Nevertherless, persistent concerns remain about the functional
consequences of delivering curative radiation doses to the larynx
and pharyngeal musculature, with the risk of ensuing chronic
edema and fibrosis, leading to voice alteration and chronic
dysphagia and potentially defeating the purpose of laryngeal
preservation [11,12]. The traditional treatment for locally
advanced laryngeal cancer has been two lateral fields matched
with an anterior supraclavicular field. This three-dimensional (3-
D) radiotherapy technique did not allow sparing of normal tissues
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which received the same tumor dose. Xerostosmia secondary to
radiation related destruction of the parotid glands, osteoradione-
crosis secondary to high mandibular dose, and hearing loss from
cochlea damage, are common sequellaes of 3-D conformal
radiotherapy (3-DRT) leading to poor patient quality of life [13–
15]. Recently, intensity-modulated (IMRT) and image-guided
radiotherapy (IGRT) have been introduced in the treatment of
head and neck cancer to decrease treatment toxicity by improving
normal tissue sparing [16–18]. Rapid dose fall off away from the
target allows significant sparing of the normal organs at risk for
complications and potentially improves patient quality of life with
these new radiotherapy techniques. The simultaneously integrated
boost (SIB) technique of IMRT and IGRT also allows selective
dose assignment to different target levels with the tumor receiving
the highest dose and subclinical disease treated to a lower dose,
thus allows more control of the radiation dose received by the
normal organs adjacent to the target. Preliminary dosimetric
studies of laryngeal cancer also demonstrated improved dose
conformality of IMRT compared to 3-DRT, potentially leading to
improved tumor control if the tumor dose can also be increased
with the integrated boost technique [19–20]. However, the
advantages of IMRT and IGRT may also be negated because of
possible marginal miss if the tumor volume is not clearly defined
[21]. Thus, accurate pre-treatment imaging such as positron
emission tomography (PET) scans is almost mandatory for
laryngeal cancer because of its superior tumor delineation
compared to CT scans [22]. Following radiotherapy, high dose
to the larynx for tumor control often lead to severe laryngeal
edema which may be interpreted as tumor recurrence. The ability
of PET scans and PET-CT to distinguish tumor recurrence from
laryngeal edema and fibrosis also make it an ideal tool for patient
follow-up to avoid unnecessary laryngeal biopsies which may cause
chondronecrosis [23–24]. We investigate in this retrospective study
the feasibility and potential benefit of IMRT and IGRT for
anatomic and functional organ preservation in combination when
FDG-PET has been used to guide target volume felineation, and
post treatment surveillance. Table 1 illustrates the potential
benefits and possible pitfalls of IMRT and IGRT compared to
3-D conformal radiotherapy.
Materials and Methods
The medical records of 27 patients undergoing curative
radiotherapy for locally advanced laryngeal cancers at the
University of Arizona Radiation Oncology Department were
retrospectively reviewed following institutional review board (IRB)
approval. The University of Arizona IRB waived the patient
consent requirement because of the retrospective nature of the
study limited to chart reviews. The patient information was de-
identified to protect patient confidentiality. Eight patients were
treated with the whole field (WF) IMRT technique on the Elekta
linear accelerator (6 MV photons) with 7 to 9 radiation beams
from February 2007 to December 2008. Following installation of
the helical Tomotherapy unit in December 2008, 19 patients were
treated with the WF IGRT technique. Prior to treatment, each
patient was simulated in the supine position with a head and neck
aquaplast mask for treatment immobilization. A computed
tomography (CT) scan with and without intravenous (IV) contrast
for treatment planning was performed in the treatment position.
The head and neck areas from the vertex to the mid thorax were
scanned with a slice thickness of 3 mm CT scan with IV contrast
was employed to outline the tumor and grossly enlarged cervical
lymph node for target volume delineation. Radiotherapy planning
was performed on the CT scan without contrast to avoid possible
interference of contrast density on radiotherapy isodose distribu-
tions. Diagnostic positron emission tomography (PET)-CT scan
planning for tumor imaging was also incorporated with CT
planning. A 0.5 cm bolus material was placed on any area of the
skin involved by the tumor and on any palpable cervical lymph
nodes. Patients treated on Tomotherapy also had 0.5 cm bolus
over the thyroid cartilage to prevent possible underdosing of the
larynx. Normal organs at risk for complication were outlined for
treatment planning (spinal cord, brain stem, bilateral cochlea,
mandible, parotid glands, bilateral eyes, and oral cavity).
Radiation therapy dose was similar for patients in both groups
using the integrated boost technique to decrease treatment
toxicity. The tumor and grossly enlarged lymph nodes (CTV1)
on CT scan with a margin (PTV1) were treated to 70 Gy in 35
fractions (2 Gy/fraction). The margins were 5 mm to 1 cm all
around CTV1 depending on anatomic location. The areas at high
risk-PTV2 (at least 1 cm around gross tumor and pathologic
cervical lymph nodes) and low risk -PTV3 (subclinical regional
lymph nodes with 5 mm margins) for tumor spread were treated
respectively to 63 Gy and 56 Gy in 35 fractions, respectively.
Minimal target coverage was 95% of the prescribed dose for all
targets with at least 99% of the prescribed dose delivered to gross
tumor and involved cervical lymph nodes. The lymph nodes in the
ipsilateral neck including the retropharyngeal lymph nodes were
treated to the base of skull if there was any cervical lymph node
enlargement (or PET-positive lymph nodes). Contralateral unin-
volved lymph nodes were treated prophylactically with the C1
vertebrae as the superior border. In cases of bilateral cervical
lymph node involvement, the bilateral neck was treated to the base
of skull to avoid any marginal miss. Mean dose to the parotid was
kept below 2600 cGy if there was no ipsilateral cervical lymph
node enlargement. Dose constraints for other normal organs at
risk (OAR) for complications were: spinal cord (45 Gy), brain stem
(50 Gy), optic chiasm (45 Gy), mandible (70 Gy to less than 30%
of the mandible).
Concurrent chemoradiation was recommended for all patients.
The type of chemotherapy regimen was left at the discretion of the
medical oncologist depending on patient functional status and co-
Table 1. Potential advantages and pitfalls of intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT)
compared to 3-dimentional conformal radiotherapy (3-D CRT).
IMRT, IGRT 3-D CRT
Advantages: Sparing of normal organs because of rapid dose fall No sparing
Tumor dose escalation possible because of different dose levels within the target volume No dose escalation
Visualization of tumor shrinkage feasible for IGRT allowing re-planning during radiotherapy No visualization
Pitfalls: Marginal miss if tumor not properly contoured leading to local recurrences. Unlikely
doi:10.1371/journal.pone.0042729.t001
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morbidities. Prophylactic percutaneous gastrostomy (PEG) feed-
ing-tube placement was also recommended for all patients prior to
treatment given expected weight loss secondary to acute toxicity
including mucositis and dysgueusia. Weekly complete blood count
(CBC) and blood chemistry work-ups were performed during
chemoradiation. Treatment breaks and weight loss were recorded
during chemoradiation. Acute and long-term toxicities were
graded according to Radiotherapy Oncology Group (RTOG)
group criteria severity scale (http://ctep.cancer.gov).
After treatment, all patients had follow-up visits at one month,
then, every three months thereafter. Clinical and direct laryngo-
scopic examination were performed at each follow up visit. PET
scan, or PET-CT imaging was performed at four months and ten
months, then yearly after treatment. All PET-positive areas were
biopsied to detect recurrence and total salvage laryngectomy (TL)
with bilateral neck dissection (BND) carried out, if biopsy was
positive. Voice quality (ability to conduct a normal conversation
over the phone or ability to communicate without difficulty at
work) was assessed at each follow-up visit. Patient ability to resume
normal oral feeding and feeding-tube dependency was also
evaluated at each visit.
Survival analysis was analyzed using Kaplan-Meier estimation.
Results
We identified 27 patients with loco-regionally advanced invasive
squamous cell carcinoma of the larynx treated at the University of
Arizona Radiation Oncology department from 2007 to 2010.
Median age at diagnosis was 63 years-old (range: 52–84 years-old).
There were 25 males and 2 females. Seventeen patients had stage
III, nine had stage IVA, and one had stage IVB disease. Twenty
six patients received concurrent chemoradiation, while one patient
who declined concurrent chemotherapy received radiotherapy
alone. Table 2 summarizes patient characteristics. Table 3
summarizes radiation dose to the larynx and other head and
neck organs. Figure 1 illustrates the dose-volume histogram of a
patient with a T3N0M0 supraglottic laryngeal cancer treated with
IGRT demonstating the feasibility of this new technique of
radiotherapy to spare the normal head and neck organs from
excessive radiation.
Chemotherapy consisted of cisplatin (P) 30 mg/m2 intrave-
nously (IV) weekly in 12 patients and cisplatin 100 mg IV on day
1, 22, and 43 of radiotherapy in 11 patient. Four patients had
induction chemotherapy with taxotere (T) 75 mg/m2 IV, cisplatin
100 mg/m2 IV followed by 5-fluorouracil (F) 1000 mg/m2 for
four days, repeated every three weeks for two cycles, followed
during radiotherapy by carboplatin IV weekly with an area under
the curve of 1.5.
At a median follow-up of 20 months (6–57 months), four
patients developed local recurrence and underwent salvage TL
and BND. One of the four patients was the patient who declined
chemotherapy, and who in addition was poorly compliant during
radiotherapy despite repeated staff warnings with a two-week
treatment break. Two of the three patients with local recurrence
developed distant metastases following salvage TL. The third is
still free of disease 30 months after treatment. The fourth just
completes his surgery for salvage. All recurrences were detected on
PET imaging, and proven by biopsy. In two patients with a
subglottic recurrence and a second base of tongue primary,
respectively, endoscopic examination was normal, with PET
imaging leading to confirmation of recurrence. Another patient
developed localized non-small cell lung cancer which was
discovered on PET imaging and treated with stereotactic body
radiotherapy. Three patients died at 11 to 14 months after
treatment. The causes of death was stroke, second lung primary,
and aspiration pneumonia, each respectively in one patient. The
2-year and 3-year survival is estimated to be 80% and 62.3%
respectively for the whole group.
Twenty patients (74%) developed grade 3–4 toxicity during
treatment, mainly mucositis (16 patients) and hematologic toxicity
(4 patients). Two patient developed aspiration pneumonia,
requiring brief intubation in one patient during the sixth week of
radiotherapy. While all patients completed radiotherapy, fifteen
(55%) had treatment breaks ranging from one to 29 days (median:
7 days) because of grade 3–4 toxicity. Median weight loss, despite
prophylactic gastrostomy tube placement, was 9 pounds (0–25
pounds). Chemotherapy was not administered, or not adminis-
tered according to the protocol in nine patients (33%). In addition
to the patient declining chemotherapy, seven had schedule
modifications due to side-effects during treatment. The patient
receiving induction TPF developed bowel obstruction after two
cycles, requiring discontinuation of the third cycle. The same
patient subsequently developed pancytopenia (white blood cells:
1300, hemoglobin: 8 g/dl, platelets: 83,000) during chemoradia-
tion requiring discontinuation of carboplatin after week 6 of
radiotherapy.
Among patients for whom a standard cisplatin regimen of
100 mg/m2 on days 1, 22, and 43 was planned, one patient
required a dose reduction to 80 mg/m2 for the first two cycles,
and did not receive the third cycle because of aspiration
pneumonia. Another patient also did not receive the third cycle
because of neutropenia (white blood cells: 1,000). Another patient
had cisplatin dose reduction to 75 mg/m2 after the second cycle
because of renal dysfunction (Cr: 1.5, BUN: 36). Among patients
receiving weekly cisplatin, two patients had protocol violations:
cisplatin was delayed at week 6 in one patient because of
neutropenia (white blood cells: 1,500) and discontinued after week
5 in another because of aspiration pneumonia. However, all
patients completed the intended dose of radiotherapy despite
treatment break.
At last follow-up, 22 of the 23 patients without recurrence
reported normal or near normal voice quality, allowing them to
communicate effectively at work or over the phone. The
remaining patient reported persistent hoarseness and voice
weakness, and had still been unable to work full time 12 months
after treatment. His follow-up visits confirmed chronic laryngeal
edema on endoscopic, with no sign of recurrence on PET imaging
at 4 and 10 months after treatment. Among the entire group of 25
patients, four (16%) were still dependent on tube feedings at 6 to
16 months after treatment, due to severe dysphagia in 2 patients,
and chronic aspiration in the other 2. Chemotherapy regimens in
these four patients were weekly cisplatin in 2 patients, three-weekly
cisplatin in one patient, and induction TPF followed by concurrent
weekly carboplatin in one patient. The patient who received TPF/
carboplatin finally died of aspiration pneumonia with no sign of
recurrence 6 months after treatment. Table 4 summarizes acute
and late toxicities following treatment for the whole group.
Discussion
To our knowledge, this is the first study looking at functional
laryngeal preservation following chemoradiation for locally
advanced laryngeal cancer with IMRT and IGRT. Even though
our patient number was small and the follow-up relatively short,
the anatomic laryngeal preservation rate we observed was similar
to that reported in the RTOG 91-11 study, at 89% if we exclude
the patient who declined chemotherapy and was non-compliant
during radiotherapy. Most patients in the RTOG 91-11 had T2-
New Radiotherapy Techniques for Laryngeal Cancer
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T3 disease because it was thought that patients with T4 disease
would have a non functional larynx following treatment [8]. Of
note, six of the patients in our study had T4 disease and would
thus have been excluded from concurrent chemoradiation in the
RTOG study. All of these patients had no sign of recurrence at 11
to 45 months after treatment demonstrating the feasibility of organ
preservation with IMRT and IGRT in T4 disease. For instance,
one patient had disease invading the soft tissue of the neck and
producing acute airway compression requiring emergency trache-
ostomy. The tumor shrank significantly during treatment allowing
removal of the tracheostomy tube after treatment (Figure 2). The
patient recovered his voice following treatment and, was able to
resume his work without any difficulty with communication. PET
imaging following treatment appeared in our patient group to be
an effective follow-up strategy, detecting recurrence in two patients
with normal endoscopic examination, thus confirming other
studies reporting that PET imaging after radiotherapy for
laryngeal cancer is helpful in detecting disease recurrence or
second primaries, and thereby making laryngeal preservation
therapy more feasible without compromising survival [23–25]. No
patient with a negative PET scan in our study had disease
recurrence, thus corroborating the accuracy of PET scan
described in the literature [26]. In fact, in addition to the benefits
provided by IMRT and IGRT, we feel that the excellent voice
preservation observed in our patients, may in part be due to the
avoidance of unnecessary biopsies in patients with negative PET
imaging, reducing the edema and scarring frequently observed
following laryngeal irradiation. In the recent past, laryngeal biopsy
has been recommended in patients with edema persisting beyond
six months following radiotherapy for laryngeal cancer [27].
However, recurrence is frequently submucosal and not visualized
on direct laryngoscopic examinations and negative biopsy results
requiring repeat procedures are common increasing the risk of
chondritis and laryngeal necrosis [28,29]. As reported in several
Figure 1. Dose-volume .histogram in a patient with T3N0M0 supraglottic laryngeal cancer illustrating the potential of image-
guided radiotherapy to deliver a high radiation dose to the gross tumor while sparing the radiosensitive normal organs. Mean
tumor dose: 75.4 Gy; mean right parotid dose (light green):11.4 Gy; mean left parotid dose (violet): 11.3 Gy; mean right (dark green) and left (pink)
cochlea dose: 2 Gy; maximummandibular dose (orange): 59.5 Gy; maximum spinal cord dose (light blue): 31.2 Gy. The radiation dose to these normal
structures was well below the threshold for normal tissue damage and could potentially improve the patient quality of life after treatment. The red
color illustrated radiation dose (70 Gy) to the gross tumor volume (gtv) while the dark blue and green color demonstrated radiation dose to the high
risk area (63 Gy) and low risk area (56 Gy) respectively. The brown color illustrated radiation dose to the pharyngeal muscles which was high (mean
67 Gy) because of the close proximity to the gross tumor and may explain the high rate of dysphagia following radiotherapy for locally advanced
laryngeal cancer.
doi:10.1371/journal.pone.0042729.g001
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studies, PET imaging has an excellent negative predicting value
after treatment, and a negative PET exam in the presence of
persistent laryngeal edema after radiotherapy is a strong argument
that such edema is benign and not due to local recurrence.
Because of the retrospective nature of the study, we did not
generally have stroboscopy data available to assess vocal cord
mobility. However, only one patient complains of hoarseness and
weakness of his voice preventing him from having a full time job as
he works as a salesman. He had chronic laryngeal edema which
did not improve over time.
The rate of severe chronic dysphagia and aspiration we
observed during and after treatment remains high and
corroborated RTOG 91-11 data [8]. Among 172 patients
randomized to concurrent chemoradiation, 77% of the patients
developed severe grade 3–4 toxicity, 5% died from treatment
toxicity, and 9% did not complete the intended dose of
radiotherapy (70 Gy). At one year, 3% of these patients could
not swallow at all, and 23% could only tolerate liquids or soft
food. Our study acute grade 3–4 mucositis and late toxicity
remained significant with concurrent chemoradiation despite
the use of IMRT, an observation corroborated in other studies
of IMRT in laryngeal cancers [30,31]. Lee et al [30] reported a
35% rate of grade 3 mucositis and laryngitis in 31 patients with
laryngeal and hypopharyngeal cancers undergoing concurrent
chemoradiation with IMRT with six patients (19%) remaining
dependent on long-term tube feedings. In another study of
IMRT for laryngeal and hypopharyngeal cancer, eight out of
36 patients (25%) who had PEG tubes inserted before or during
radiotherapy remained tube dependent more than 12 months
after treatment. Given the close proximity of the pharyngeal
musculature, severe dysphagia and aspiration remains unavoid-
able with the delivery of curative radiation doses to the larynx.
Caglar et al demonstrated that the aspiration risk following
IMRT for head and neck cancer was proportional to the
volume of the inferior pharyngeal constrictor muscles receiving
.50 Gy [32]. While it is thus not surprising that aspiration and
long-term feeding-tube dependency remain prevalent after
IMRT for laryngeal cancer, the aspiration risk is significantly
lower following IMRT than following conventional radiother-
apy with two lateral fields and a supraclavicular fields. Nguyen
et al reported a 54% aspiration rate after concurrent
chemoradiation for locally advanced laryngeal cancer with
conventional radiotherapy [33]. In another study, 84% of the
patients with definitive conventional radiotherapy for laryngeal
cancer reported chronic aspiration [34]. Of note, aspiration
after radiotherapy for head and neck cancer is often silent and
can cause death from aspiration pneumonia if undetected
[35,36]. Compared to conventional radiotherapy, IMRT and
IGRT provide more homogeneous dose coverage of target
volume and steeper dose gradients, potentially decreasing the
radiation dose to the pharyngeal muscles and thereby decreas-
ing the aspiration rate [37]. Nonetherless, severe dysphagia and
aspiration remain significantly high with IMRT and IGRT for
locally advanced laryngeal cancer. Following treatment, swal-
Table 2. Patient characteristics.
IGRT IMRT Total
Patient No 19 8 27
Age
Median 60 68 63
Range 52–78 60–84 52–84
Sex
Male 17 8 25
Female 2 0 2
Squamous histology 19 8 27
Sites
Glottis 5 6 11
Supraglottis 14 2 16
Stages
III 11 6 17
IVA 7 2 9
IVB 1 0 1
T stages
T1 0 2 2
T2 5 2 7
T3 9 3 12
T4 5 1 6
Neck nodes
N0 12 4 16
N1 4 3 7
N2 3 1 4
Treatment
Radiotherapy alone 1 0 1
Chemoradiation 18 8 26
IGRT: Image-guided radiotherapy; IMRT: Intensity-modulated radiotherapy.
doi:10.1371/journal.pone.0042729.t002
Table 3. Dose distribution in Gray (Gy) to the larynx and
other head and neck organs.
Mean (range) Max (range)
Larynx 72.5 (70.5–76.7) 76.1 (71.9–82.2)
Spinal cord 39.1 (28.9–44.6)
Mandible 37.9 (23–56.1) 64 (46.4–74.8)
Right TMJ 12.8 (1.6–41) 34.9 (2.1–46.6)
Left TMJ 9.7 (1.8–23) 22.4 (2.3–44.7)
Right parotid 27.7 (10–40.7)
Left parotid 32.4 (14.4–40.5)
Right cochlea 9.4 (1–35) 11.9 (1.9–44.9)
Left cochlea 8.9 (1–35.9) 17.5 (1–47.1)
TMJ: Temporo-mandibular joint.
doi:10.1371/journal.pone.0042729.t003
Table 4. Acute and late toxicities following intensity-
modulated and image-guided radiotherapy for 27 patients
with locally advanced laryngeal cancer.
Acute Late
Grade 3–4 mucositis (16) Long-term tube feedings (4)
Grade 3–4 hematologic toxicity (4) Aspiration pneumonia (1)
Aspiration pneumonia (2)
Bowel obstruction (1)
Herpes Zoster (1)
doi:10.1371/journal.pone.0042729.t004
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lowing therapy should be initiated early within four to six weeks
if dysphagia or aspiration are present [38]. Another possible
investigation is the use of Amifostine, a radiation protector,
which has been proven to decrease late dysphagia following
radiotherapy for head and neck cancer [39]. Amifostine should
be considered in future prospective trials to investigate whether
it can reduce aspiration rate [39].
The limitations of the present study include its retrospective
nature, the small number of patients, the short follow-up, and the
absence of a matched controlled group treated with 3-D conformal
technique. However, it demonstrates the feasibility of modern
radiotherapy techniques including IMRT and IGRT for anatomic
and functional laryngeal preservation in patients with locally
advanced laryngeal cancers. Further prospective studies with
larger patient numbers should be performed with these techniques,
in order to try confirm their positive impact on patient quality of
life.
Conclusions
New radiotherapy techniques such as IMRT and IGRT may be
effective for anatomic and functional laryngeal preservation in
patients with locally advanced laryngeal carcinoma. However,
severe dysphagia and aspiration still remain limiting factors for
surviving patients most likely secondary to excessive radiation dose
to the pharyngeal muscles. Clinicians should be alerted about the
risk of aspiration pneumonia for proper management.
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Figure 2. Illustrating the effectiveness of intensity-modulated and image-guided radiotherapy to achieve local control in T4
laryngeal cancer. The tumor invaded the thyroid cartilage and soft tissue of the neck and produced acute airway obstruction requiring emergency
tracheostomy. A repeat CT scan at 40 Gy demonstrated significant shrinkage of the tumor allowing removal of the tracheostomy tube after
treatment. The patient is disease-free 45 months after treatment and conserve a normal voice allowing him to work part-time after retirement.
doi:10.1371/journal.pone.0042729.g002
New Radiotherapy Techniques for Laryngeal Cancer
PLOS ONE | www.plosone.org 6 August 2012 | Volume 7 | Issue 8 | e42729
References
1. Tupchong L, Scott CB, Blitzer PH, Marcial VA, Lowry LD, et al. (1991)
Randomized study of preoperative versus postoperative radiation therapy in
advanced head and neck carcinoma: long-term follow-up of RTOG study.
Int J Radiat Oncol Biol Phys 20:21–28.
2. DeSanto LW, Olsen KD, Perry WC, Rohe DE, Keith RL (1995) Quality of life
after surgical treatment of cancer of the larynx. Ann Otol Rhinol Laryngol
104:763–769.
3. Deshmane VH, Parikh HK, Pinni S, Parikh DM, Rao RS (1995) Laryngectomy:
a quality of life assessment. Indian J Cancer 32:121:130.
4. Hilgers FJ, Ackerstaff AH, Aaronson NK, Schouwenburg PF, Van Zandwijk
N(1990) Physical and psychosocial consequences of total laryngectomy. Clin
Otolaryngol 15:421–425.
5. Kuntz AL, Weymuller EA (1999) Impact of neck dissection on quality of life.
Laryngoscope 8:1334–1338.
6. Rogers SN, Lowe D, Brown JS, Vaughan ED (1999) The University of
Washington head and neck cancer measure as a predictor of outcome following
primary surgery for oral cancer. Head Neck 21:394–401.
7. Department of Veterans Affairs Laryngeal Cancer Study Group (1991)
Induction chemotherapy plus radiation compared to surgery plus radiation in
patients with advanced laryngeal cancer: The department of veterans affair
laryngeal cancer study group (1991). N Engl J Med 324:1685–1690.
8. Forastiere AA, Goepfert H, Maor M, et al. (2003) Concurrent chemotherapy
and radiotherapy for organ preservation in advanced laryngeal cancer.
N Engl J Med 349:2091–2098.
9. Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, et al. (2009) Phase
III randomized trial on larynx preservation comparing sequential and
alternating chemotherapy and radiotherapy. J Nat Cancer Inst 101:142–152.
10. Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, et al. (2009) Sequential
therapy for the locally advanced larynx and hypopharyngeal cancer subgroup in
TAX 324: survival, surgery, and organ preservation. Ann Oncol 20:921–927
11. Sanguineti G, Adapala P, Endres EJ, Brack C, Fiorino C, et al. (2007)
Dosimetric predictors of laryngeal edema. Int J Radiat Oncol Biol Phys 68:741–
749.
12. Nguyen NP, Moltz CC, Frank C, Vos P, Millar C, et al. (2007) Aspiration rate
following nonsurgical therapy for laryngeal cancer. ORL 69:116–120.
13. Braaksma MMJ, Wijers OB, van Sornsen de Koste JR, van der Est H, Schmitz
PI, et al. (2003) Optimisation of conformal radiation therapy by intensity-
modulation: cancer of the larynx and salivary function. Radiother Oncol
66:291–302.
14. Zevallos JP, Mallen MJ, Lam CY, Karam-Hage M, Blalock J, et al. (2009)
Complications of radiotherapy in laryngopharyngeal cancer. Effects of a
smoking cessation program. Cancer 115:4636–4644.
15. Liberman PHP, Schultz C, Gomez VSG, Carvalho AL, Pelizzon AC, et al.
(2004) Auditory effects after organ preservation protocol for laryngeal/
hypopharyngeal carcinomas. Arch Otolaryngol Head Neck Surg 130:1265–
1268.
16. Nguyen NP, Vock C, Chi A, Ewell L, Vos P, et al. (2012) Effectiveness of
intensity-modulated and image-guided radiotherapy to spare the mandible from
excessive radiation. Oral Oncol 48:653–657
17. Nguyen NP, Smith-Raymond L, Vinh-Hung V, Sloan D, Davis R, et al. (2011)
Feasibility of Tomotherapy to spare the cochlea from excessive radiation in head
and neck cancer. Oral Oncol 47:900–904
18. Nguyen NP, Vos P, Vinh-Hung V, Ceizyk M, Smith-Raymond L, et al. (2012)
Feasibility of image-guided radiotherapy based on helical tomotherapy to reduce
contralateral parotid dose in head and neck cancer. BMC Cancer, epublication.
19. Penagaricano JA, Ratanatharathorn V, Papanikolaou N, Yan Y (2004) Intensity-
modulated radiation therapy reduces the dose to the normal tissue in T2N0M0
squamous cell carcinoma of the glottic larynx. Dosimetry 29:254–257.
20. Dogan N, King S, Emami B, Mohideen N, Mirkovic N, et al. (2003) Assessment
of different IMRT delivery methods on target coverage and normal tissue
sparing. Int J Radiat Oncol Biol Phys 57:1480–1491.
21. Chen AM, Farwell DG, Luu Q, Chen LM, Vijayakumar S, et al. (2011)
Marginal misses after postoperative intensity-modulated radiotherapy for head
and neck cancer. Int J Radiat Oncol Biol Phys 80:1423–1429.
22. Gordin A, Daitzchman M, Doweck I, Yefremov N, Golz A, et al. (2006)
Fluorodeoxyglucose-Positron emission Tomography/Computed Tomography
imaging in patients with carcinoma of the larynx: diagnostic accuracy and
impact on management. Laryngoscope 116:273–278.
23. Salaun PY, Abgral R, Querellou S, Couturier O, Valette G, et al. (2007) Does
18fluoro-fluorodeoxyglucose positron emission tomography improve recurrence
detection in patients treated for head and neck squamous cell carcinoma with
negative clinical follow-up? Head Neck 29:1125–1130.
24. Oe A, Kawabe J, Torii K, Kawamura E, Kotani J, et al. (2006) Detection of
local residual tumor after laryngeal cancer treatment using FDG-PET. Ann Nucl
Med 21:9–13.
25. Brouwer J, de Bree R, Comans EFI, Akarriou M, Langendijk JA, et al. (2008)
Improved detection of recurrent laryngeal tumor FDG-PET as initial method.
Radiother Oncol 87:217–220.
26. van Hooren ACG, Brouwer J, de Bree R, Hoekstra OS, Leemans CR, et al.
(2009) The cost effectiveness of FDG-PET in selecting patients with suspicion of
recurrent laryngeal carcinoma after radiotherapy for direct laryngoscopy. Eur
Arch Otorhinolaryngol 266:1441–1448.
27. Ward PD, Calcaterra TC, Kagan AR (1975) The enigma of post-radiation
edema and residual or recurrent carcinoma of the larynx and pyriform fossa.
Laryngoscope 85:522–529.
28. Brouwer J, bogar EJ, de Bree R, Langendijk JA, Castelijns JA, et al. (2004)
Detecting recurrent laryngeal carcinoma after radiotherapy: room for improve-
ment. Eur Arch Otorhinolaryngol 261:417–422.
29. Zbaren P, Caversaccio M, Thoeny HC, Nuyens M, Curshmann J, et al. (2006).
Radionecrosis or tumor recurrence after radiation of laryngeal hypopharyngeal
carcinomas. Otolaryngol Head Neck Surg 135:838–843.
30. Lee NY, O’Meara W, Chan K, Della-Bianca C, Mechalakos JG, et al. (2007)
Concurrent chemotherapy and intensity-modulated radiotherapy for locore-
gionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol
Biol Phys 60:459–468.
31. Studer G, Peponi E, Kloeck S, Dossenbach T, Huber G, et al. (2010) Surviving
hypopharynx-larynx carcinoma in the era of IMRT. Int J Radiat Oncol Biol
Phys 77:1391–1396.
32. Caglar HB, Tishler RB, Othus M, Burke E, Li Y, et al. (2008) Dose to larynx
predicts for swallowing complications after intensity-modulated radiotherapy.
Int J Radiat Oncol Biol Phys 72:1110–1118.
33. Nguyen NP, Moltz CC, Frank C, Vos P, Millar C, et al. (2007) Aspiration rate
following nonsurgical therapy for laryngeal cancer. ORL 69:116–120.
34. Hutcheson KA, Barringer DA, Rosenthal DI, May AH, Roberts DB, et al.
(2008) Swallowing outcomes after radiotherapy for laryngeal carcinoma. Arch
Otolaryngol Head Neck Surg 134:178–183.
35. Nguyen NP, Moltz CC, Frank C, Millar C, Smith HJ, et al. (2007) Effectiveness
of the cough reflex in patients with aspiration following radiation for head and
neck cancer. Lung 185:243–248.
36. Nguyen NP, Smith HJ, Dutta S, Alfieri A, North D, et al. (2007) Aspiration
occurrence during chemoradiation for head and neck cancer. Anticancer Res
27:1669–1672.
37. Clark CH, Bidmead MA, Mubata CD, Harrington KJ, Nutting CM (2004)
Intensity-modulated radiotherapy improves target coverage, spinal cord sparing
and allows dose escalation in patients with locally advanced cancer of the larynx.
Radiother Oncol 70:189–198.
38. Nguyen NP, Moltz CC, Frank C, Smith HJ, Nguyen PD, et al. (2007) Impact of
swallowing therapy on aspiration rate following treatment for locally advanced
head and neck cancer. Oral Oncol 43:352–357.
39. Buntzel J, Glatzel M, Mucke R, Micke O, Bruns F (2007) Influence of amifostine
on late radiation-toxicity in head and neck cancer—a follow-up study.
Anticancer Res 2007;27:1953–1956.
New Radiotherapy Techniques for Laryngeal Cancer
PLOS ONE | www.plosone.org 7 August 2012 | Volume 7 | Issue 8 | e42729
